Recell
Device
Avita Medical Americas, LLC
Total Payments
$2.9M
Transactions
4,150
Doctors
1,953
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.5M | 2,826 | 1,554 |
| 2023 | $1.4M | 1,324 | 543 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 173 | 60.3% |
| Consulting Fee | $418,511 | 191 | 14.5% |
| Honoraria | $230,575 | 105 | 8.0% |
| Food and Beverage | $212,860 | 3,173 | 7.4% |
| Travel and Lodging | $164,031 | 462 | 5.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $111,022 | 36 | 3.8% |
| Charitable Contribution | $10,300 | 5 | 0.4% |
| Entertainment | $328.22 | 5 | 0.0% |
Payments by Type
Research
$1.7M
173 transactions
General
$1.1M
3,977 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Prospective Post-Market Clinical Study Investigating Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin Cells | Avita Medical Americas, Llc | $850,075 | 0 |
| A Prospective Post-Market Clinical Study Investigating Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin Cells | Avita Medical Americas, LLC | $256,987 | 0 |
| Skin rejuvenation study with Spray-On Skin Cells | Avita Medical Americas, LLC | $202,966 | 0 |
| A Prospective Post-Market Clinical Study Investigating Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells | Avita Medical Americas, Llc | $197,706 | 0 |
| A Prospective Multicenter Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of RECELL System Combined with Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction | Avita Medical Americas, LLC | $125,810 | 0 |
| A Prospective Blinded Within-Subject Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions | Avita Medical Americas, LLC | $107,473 | 0 |
Ad
Manufacturing Companies
Product Information
- Type Device
- Total Payments $2.9M
- Total Doctors 1,953
- Transactions 4,150
About Recell
Recell is a device associated with $2.9M in payments to 1,953 healthcare providers, recorded across 4,150 transactions in the CMS Open Payments database. The primary manufacturer is Avita Medical Americas, LLC.
Payment data is available from 2023 to 2024. In 2024, $1.5M was paid across 2,826 transactions to 1,554 doctors.
The most common payment nature for Recell is "Unspecified" ($1.7M, 60.3% of total).
Recell is associated with 6 research studies, including "A Prospective Post-Market Clinical Study Investigating Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin Cells" ($850,075).